Artificial liver support devices for fulminant liver failure

Area of Science:

• Biomedical Engineering
• Hepatology
• Regenerative Medicine

Background:

• Fulminant hepatic failure (FHF) presents a critical medical challenge, often requiring liver transplantation.
• Toxin accumulation is a suspected contributor to FHF's clinical manifestations.
• Early interventions focused on toxin removal through blood and plasma exchange.

Purpose of the Study:

• To review the evolution and efficacy of artificial liver support (ALS) devices.
• To evaluate the limitations of purely mechanical ALS systems.
• To explore the potential of hybrid ALS systems combining mechanical and biologic functions.

Main Methods:

• Review of historical and current artificial liver support technologies.
• Analysis of mechanical devices: hemodialysis, charcoal hemoperfusion, hemodiabsorption.
• Examination of biologic support: extracorporeal perfusion, cross-circulation, hepatocyte transplantation.
• Evaluation of hybrid systems integrating mechanical and biologic components within bioreactors.

Main Results:

• Mechanical ALS devices have not demonstrated long-term survival benefits in controlled studies.
• Biologic replacement strategies are necessary to address the liver's functional deficits.
• Hybrid ALS devices show promise, particularly as a bridge to transplantation, but optimal configurations are still under investigation.

Conclusions:

• Neither purely mechanical nor purely biologic artificial liver support is sufficient for FHF.
• Hybrid artificial liver support systems represent the most promising approach currently.
• Further research is needed to optimize bioreactor design and determine the ideal type and quantity of biologic material for hybrid systems.